Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3454738 in moderate-to-severe atopic dermatitis
NCT05911841Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ucenprubart in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Eczema Area and Severity Index 75 at 16 weeks. Started Jun 2023; status: terminated.
02
Drugs
ucenprubart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05911841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911841.